Specifically, the modification of TLR4 signaling pathway has previously gained attention because of its ability to detect lipopolysaccharides (LPS) on Gam-negative bacteria, as well as several DAMPs.2, 4, 6, 7, 8Despite promising preclinical outcomes, the phase 3 trial of the TLR4/MD2 inhibitor eritoran in patients with sepsis did not yield any clinical benefit.9The receptor for advanced glycosylation end products (RAGE) and the triggering receptor expressed on myeloid cells-1 (TREM-1) are two additional PRRs that have been the subject of research. This evidence concerns the gene TLR4 and Sepsis.